TG Therapeutics Inc (TGTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.75B
Last updated: Nov 17, 2026 at 11:06 AM ET
TG Therapeutics Inc (TGTX) P/E Ratio & Valuation History
TG Therapeutics (TGTX) trades at 87.2x trailing earnings and 11.1x sales. Its P/S of 11.1x is below its 5-year median of 13.2x. Its forward P/E is 29.9x. The median P/E across 3 similar companies is 39.6x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 191.6% higher over the next year. Its free cash flow yield is 0.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 87.2x |
| Forward P/E | 29.9x |
| Price to sales | 11.1x |
| Price to book | 14.7x |
| EV/EBITDA | 61.9x |
| Price to FCF | 511.8x |
| EV/FCF | 526.9x |
| PEG | 1.6 |
| FCF yield | 0.2% |
Historical Medians
Against its 10-year medians, its P/B is 23.5% above 11.9x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 11.1x | 13.2x | N/A |
| P/B | 14.7x | 13.5x | 11.9x |
Valuation History
Over the 5 of the 10 year ends shown that have a P/S, its P/S ranged from 7.3x in 2025 to 571.7x in 2022. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $29.81 | 59.6x | 7.3x | 7.3x |
| 2024 | $30.10 | 215.0x | 13.7x | 21.7x |
| 2023 | $17.08 | N/A | 10.4x | 15.2x |
| 2022 | $11.83 | N/A | 571.7x | 27.7x |
| 2021 | $19.00 | N/A | 375.8x | 10.6x |
| 2020 | $52.02 | N/A | N/A | 12.4x |
| 2019 | $11.10 | N/A | N/A | 27.5x |
| 2018 | $4.10 | N/A | N/A | 13.8x |
| 2017 | $8.20 | N/A | N/A | 8.1x |
| 2016 | $4.65 | N/A | N/A | 6.4x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TGTX
What is TGTX's forward P/E ratio?
TG Therapeutics has a forward P/E ratio of 29.9x.
Is TGTX stock overvalued?
GNG's valuation label for TGTX is Fairly valued. Its P/E of 87.2x compares with a median of 39.6x across 3 similar companies.
What is TGTX's price to sales ratio?
TG Therapeutics has a price to sales ratio of 11.1x.
What is TGTX's PEG ratio?
TG Therapeutics has a PEG ratio of 1.6.
TGTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors